Life Sciences Knowledge Hub

Regulatory & Compliance, explained practically.

A learning resource for teams working with GxP computerized systems, quality processes, electronic records, data integrity and digital technologies across Life Sciences.

Industry Scope

Where computerized systems meet regulated processes

The compliance question is not simply “Is this software validated?” It is “What is the intended use, what is the GxP impact, what could go wrong, and what evidence demonstrates control?”

Pharmaceutical & Biotech

  • Manufacturing & batch records
  • Laboratory systems
  • Quality systems
  • Supply chain & warehouse systems

Clinical & Pharmacovigilance

  • Clinical systems & data
  • Safety case processing
  • Medical review workflows
  • Electronic records and data

Medical Devices

  • Quality management systems
  • Production software
  • Software supporting device processes
  • Risk-based software assurance
ISPE / GAMP® 5

What is ISPE and why does GAMP® 5 matter?

ISPE is the International Society for Pharmaceutical Engineering. Its GAMP® community provides practical good-practice guidance for computerized systems in regulated Life Sciences environments. GAMP® 5 promotes a lifecycle, risk-based and patient-centric approach rather than a single prescriptive validation method.

Key objective

Help organizations achieve computerized systems that are effective, reliable, fit for intended use and compliant with applicable requirements.

Risk-based thinking

Scale controls and evidence according to patient safety, product quality, data integrity and process risk.

Critical thinking

Use knowledgeable SMEs to determine what matters, what evidence is sufficient and where deeper assurance is justified.

Reference: ISPE GAMP® overview and GAMP® 5 Second Edition.

Core Regulatory Topics

Key areas to understand

21 CFR Part 11

Consider electronic records and electronic signatures, controls, system validation where applicable, access, audit trails and record protection within the relevant scope.

EU GMP Annex 11

For GMP computerized systems, Annex 11 emphasizes validation, qualified infrastructure, lifecycle risk management, data integrity and maintaining control.

Data Integrity

Data should remain reliable and accurate. Controls should address the risks created by processes, technologies, interfaces, users and business models.

Quality Risk Management

Identify hazards, evaluate impact, determine controls and document rationale for the depth of assurance.

Supplier & Cloud Oversight

Assess suppliers, responsibilities, service changes, configuration, continuity, security, data access and exit considerations.

Lifecycle Governance

Maintain control through change control, incidents, CAPA, periodic review, access management, backup/recovery and retirement.

Regulatory requirements and guidance have different legal status and applicability. Always assess the specific product, process, system, jurisdiction and intended use before deciding what controls are required.

References: EU GMP Annex 11 and FDA Data Integrity guidance.

SDLC / V-Model

Software lifecycle and verification

The V-Model is a useful way to visualize how requirements and design decisions connect to corresponding verification activities. Modern GAMP® practice also supports iterative and incremental development; the model should be adapted to the actual lifecycle.

01

Concept

Business need

02

URS

User needs

03

Functional

What the system must do

04

Design

How it will work

05

Build / Configure

Create solution

06

Verification

Test against requirements

07

Release

Approve for intended use

08

Operate

Maintain control

Need help applying this?

Learn independently—or approach ILAP Advisory when you have a requirement.

ILAP Advisory can support focused discussions around GxP, Non-GxP, SOX and computerized-system compliance requirements, including risk assessment, CSV/CSA strategy, documentation, evidence and lifecycle considerations. Educational content remains available for readers who simply want to learn.

Request an Advisory Discussion